WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 44th Annual Health Care Conference. Details for the company’s participation are as follows: Fireside Chat Date: Monday, March 4, 2024Fireside Chat Time: 2:10 pm ET The webcast for this conference may be accessed at the “ ...

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock. Arcutis is selling 15,789,474 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $9.50 per share. All shares of common stock to be sold in the offering a ...

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants in this o ...

Core Insights - Arcutis Biotherapeutics has entered a strategic collaboration with Sato Pharmaceutical for the development and commercialization of topical roflumilast in Japan, which includes a $25 million upfront payment and potential milestone payments totaling $40 million [1][3] - The partnership aims to provide a novel non-steroidal treatment option for millions of Japanese patients suffering from inflammatory skin diseases [1][2] Financial Terms - Arcutis will receive an upfront payment of $25 million and may earn an additional $40 million based on achieving specific regulatory and sales milestones [3] - The company is also eligible for tiered, low double-digit percentage royalties from the sales of the product in Japan [3] Product Information - Topical roflumilast is a next-generation phosphodiesterase type 4 (PDE4) inhibitor, indicated for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis [1][4] - The product is being developed in cream and foam formulations, which are designed to be effective and well-tolerated for patients [2][4] Company Background - Arcutis Biotherapeutics focuses on innovations in immuno-dermatology and has a growing portfolio that includes FDA-approved products targeting immune-mediated dermatological diseases [8] - Sato Pharmaceutical is committed to healthcare innovation and provides high-quality products, particularly in dermatology [9]

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Conference Call February 27, 2024 8:30 AM ET Company Participants Derek Cole - IR Frank Watanabe - President and CEO Todd Edwards - CCO Patrick Burnett - CMO John Smither - CFO Conference Call Participants Tyler Van Buren - TD Cowen Uy Ear - Mizuho Chris Shibutani - Goldman Sachs Serge Belanger - Needham Vikram Purohit - Morgan Stanley Sean Kim - Jones Trading Operator Good day and welcome to the Arcutis Biotherapeutics' 2023 Fourth Quarter and Fu ...

Q4 net product revenues for ZORYVE® (roflumilast) cream 0.3% were $13.5 million, a 357% increase compared to the fourth quarter of 2022 and a 67% increase compared to the third quarter of 2023; driven by sequential improvement in gross-to-net (GTN) in the mid 60 percent range, as well as sustained demand growthReceived U.S. Food and Drug Administration (FDA) approval for ZORYVE® (roflumilast) topical foam, 0.3%, for the treatment of seborrheic dermatitis in adults and children down to age 9 in December 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Inco ...

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Q4 net product revenues for ZORYVE® (roflumilast) cream 0.3% were $13.5 million, a 357% increase compared to the fourth quarter of 2022 and a 67% increase compared to the third quarter of 2023; driven by sequential improvement in gross-to-net (GTN) in the mid 60 percent range, as well as sustained demand growth • Received U.S. Food and Drug Administration (FDA) approval for ZORYVE® (roflumilast) topical foam ...

sruilk/iStock via Getty Images Investment Overview Arcutis (NASDAQ:ARQT) IPO'd back in January 2020, raising ~$160m via the issuance of 9.375m shares priced at $17 per share. At the time, the company described itself as follows: a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis is currently developing three novel compounds (ARQ-151, ARQ-154 and ARQ-252) f ...

Core Insights - Arcutis Biotherapeutics has launched ZORYVE® (roflumilast) topical foam, the first new drug approved for seborrheic dermatitis in over two decades, which is now available in pharmacies [1][2] - ZORYVE foam is a steroid-free treatment option that provides rapid disease clearance and significant reduction in itch for patients aged 9 and older [1][6] - The product is expected to address unmet needs in the treatment of seborrheic dermatitis, a condition affecting over 10 million people in the U.S. [1][2] Product Details - ZORYVE foam is indicated for the treatment of seborrheic dermatitis in patients aged 9 years and older [6] - The foam is designed for once-daily application and is suitable for use on various skin and hair types, as well as across the full spectrum of disease severity [2] - Clinical trials showed that over 50% of subjects achieved complete clearance, and 75% reached IGA treatment success at 8 weeks, with over 40% achieving success as early as 2 weeks [2] Market Positioning - The launch of ZORYVE foam marks Arcutis' second commercial product in the U.S., with strong reimbursement support from major pharmacy benefit managers [2] - The company aims to establish ZORYVE as a new standard of care for seborrheic dermatitis, filling a significant gap in treatment options [2][3] Patient Support Programs - Arcutis has introduced the ZORYVE Direct Program to assist patients in accessing their prescribed medication, including a savings card program to reduce out-of-pocket costs for eligible patients [3] - The company also offers the Arcutis Cares™ patient assistance program for uninsured or underinsured patients [3] Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on developing innovative treatments for immune-mediated dermatological diseases [5] - The company has a growing portfolio that includes two FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions [5]